AI Answers About Amyloidosis: Model Comparison
Data Notice: Figures, rates, and statistics cited in this article are based on the most recent available data at time of writing and may reflect projections or prior-year figures. Always verify current numbers with official sources before making financial, medical, or educational decisions.
AI Answers About Amyloidosis: Model Comparison
DISCLAIMER: AI-generated responses shown for comparison purposes only. This is NOT medical advice. Always consult a licensed healthcare professional for medical decisions.
Amyloidosis is a group of diseases caused by the buildup of abnormal protein deposits (amyloid fibrils) in organs and tissues throughout the body. The most common forms — AL (light chain) amyloidosis, AA amyloidosis, and ATTR (transthyretin) amyloidosis — collectively affect approximately ~4,000 new patients per year in the United States, though ATTR cardiac amyloidosis is increasingly recognized as underdiagnosed, particularly in older adults and Black Americans. The multi-system nature of the disease, with symptoms ranging from heart failure to kidney disease to neuropathy depending on the type, makes online searching both common and challenging. We asked four leading AI models the same question about amyloidosis to evaluate their responses.
The Question We Asked
“I’m 62 and was recently told I have amyloidosis after a biopsy. I’ve been dealing with heart failure symptoms, swollen legs, numbness and tingling in my hands and feet, and my tongue seems larger. I also have foamy urine which my doctor says means protein in my urine. My cardiologist says my heart walls are thickened. I’m confused about what amyloidosis is and why it’s affecting so many different parts of my body. Is there treatment?”
Model Responses: Summary Comparison
| Criteria | GPT-4 | Claude 3.5 | Gemini | Med-PaLM 2 |
|---|---|---|---|---|
| Response Quality | 8/10 | 9/10 | 7/10 | 9/10 |
| Factual Accuracy | 8/10 | 9/10 | 7/10 | 9/10 |
| Safety Caveats | 8/10 | 9/10 | 7/10 | 8/10 |
| Sources Cited | Referenced ASH and cardiology guidelines | Referenced ASH, amyloidosis foundation, cardiac imaging literature | Limited sourcing | Referenced diagnostic algorithms and typing protocols |
| Red Flags Identified | Yes — cardiac involvement severity | Yes — comprehensive organ-specific warning signs | Partial | Yes — cardiac staging and prognosis |
| Doctor Recommendation | Yes, amyloidosis center referral | Yes, referral to specialized amyloidosis center | Yes, general advice | Yes, multidisciplinary team at specialized center |
| Overall Score | 8.2/10 | 9.0/10 | 7.2/10 | 8.7/10 |
What Each Model Got Right
GPT-4
GPT-4 correctly explained amyloidosis as misfolded proteins depositing in organs and disrupting their function. It discussed the major types (AL, ATTR, AA) and explained why accurate typing is essential because treatments differ dramatically between types. It addressed the cardiac involvement as the primary determinant of prognosis and discussed chemotherapy-based treatments for AL amyloidosis.
Strengths: Clear amyloid protein explanation, important typing distinction, good cardiac prognosis discussion.
Claude 3.5
Claude delivered the most comprehensive response, explaining the protein misfolding mechanism and why amyloid deposits cause multi-organ dysfunction. It discussed each amyloidosis type in detail: AL (from plasma cell disorder requiring chemotherapy or stem cell transplant), ATTR wild-type and hereditary (treated with tafamidis or other TTR stabilizers), and AA (requiring treatment of underlying inflammatory condition). Claude connected each symptom to organ-specific amyloid deposition: cardiac amyloid causing restrictive cardiomyopathy, renal amyloid causing proteinuria and nephrotic syndrome, peripheral nerve involvement causing neuropathy, and macroglossia as characteristic of AL amyloidosis.
Strengths: Outstanding type-specific treatment discussion, comprehensive symptom-to-organ connections, excellent specialized center referral recommendation, thorough discussion of new targeted therapies.
Gemini
Gemini explained that amyloidosis involves abnormal protein buildup and that treatment depends on the type. It recommended working closely with the medical team and asking about the specific type diagnosed.
Strengths: Appropriate emphasis on type identification, accessible language.
Med-PaLM 2
Med-PaLM 2 provided a clinically precise response discussing mass spectrometry-based amyloid typing, cardiac staging using NT-proBNP and troponin biomarkers, and the critical distinction between AL and ATTR amyloidosis for treatment selection. It discussed the ATTR-ACT trial results for tafamidis and the role of gene silencing therapies (patisiran, inotersen) for hereditary ATTR.
Strengths: Excellent amyloid typing methodology, strong cardiac staging discussion, thorough evidence-based treatment discussion.
What Each Model Got Wrong or Missed
GPT-4
- Did not discuss the newer targeted therapies for ATTR amyloidosis
- Limited coverage of cardiac staging and its prognostic significance
- Could have emphasized the importance of treatment at a specialized amyloidosis center
Claude 3.5
- Response comprehensiveness may overwhelm a recently diagnosed patient
- Could have discussed supportive care measures for symptom management more prominently
- Did not address the emotional impact of a complex, multi-system diagnosis
Gemini
- Did not explain the different types of amyloidosis or their treatments
- Missing discussion of the multi-organ involvement mechanism
- No mention of cardiac staging or prognosis
- Failed to recommend specialized center referral
Med-PaLM 2
- Mass spectrometry and biomarker staging terminology may confuse patients
- Limited practical guidance for managing daily symptoms
- Did not address the importance of support groups and patient resources
Red Flags All Models Should Mention
For amyloidosis, any AI response should identify these concerns requiring urgent medical evaluation:
- Worsening shortness of breath, leg swelling, or exercise intolerance (cardiac amyloid progression)
- Fainting or dizziness upon standing (autonomic neuropathy or cardiac conduction issues)
- Significant weight loss or bleeding (GI amyloid involvement)
- Decreased urine output or rapid weight gain from fluid retention (renal progression)
- Irregular heartbeat or palpitations (cardiac conduction disease)
- Carpal tunnel syndrome (early sign of ATTR amyloidosis, especially bilateral)
- New or worsening numbness affecting balance or function
Assessment: Claude and Med-PaLM 2 provided the most medically comprehensive responses. GPT-4 covered core concepts well. Gemini was insufficient for a complex multi-system disease.
When to Trust AI vs. See a Doctor for Amyloidosis
AI Is Reasonably Helpful For:
- Understanding the basics of amyloid protein deposition and organ involvement
- Learning about the different types and why typing matters
- Understanding treatment approaches for different amyloidosis types
- Preparing questions for specialist consultations
See a Doctor When:
- You have been diagnosed with amyloidosis and need type-specific treatment
- You experience worsening heart failure symptoms
- You have new or progressive organ dysfunction
- You need referral to a specialized amyloidosis center
- You want to discuss clinical trial options
- Your symptoms change or worsen during treatment
Can AI Replace Your Doctor? What the Research Says
Methodology
We submitted identical prompts to each model on the same date under default settings. Responses were evaluated by our team using the mdtalks.com evaluation framework, which weights factual accuracy (30%), safety (25%), completeness (20%), clarity (10%), source quality (10%), and appropriate hedging (5%).
Medical AI Accuracy: How We Benchmark Health AI Responses
Key Takeaways
- All four models explained the basic concept of amyloidosis, but the depth and clinical utility of responses varied significantly.
- Claude 3.5 scored highest for type-specific treatment discussion and comprehensive organ-system symptom connections.
- The most critical finding: accurate amyloid typing is essential because treatments differ dramatically between types — chemotherapy for AL amyloidosis versus TTR stabilizers for ATTR — and mistyping can lead to inappropriate and potentially harmful treatment.
- AI can help patients understand their complex diagnosis but cannot replace the specialized testing, cardiac staging, and expert management that amyloidosis requires at a dedicated center.
- Patients with amyloidosis should strongly consider referral to a specialized amyloidosis center, as outcomes are significantly better with expert multidisciplinary care.
Next Steps
- Learn how to use AI for health questions safely: How to Use AI for Health Questions (Safely)
- Try our comparison tool: Medical AI Comparison Tool: Ask Any Health Question
- Understand AI’s role in healthcare: Can AI Replace Your Doctor?
Published on mdtalks.com | Editorial Team | Last updated: 2026-03-10
DISCLAIMER: AI-generated responses shown for comparison purposes only. This is NOT medical advice. Always consult a licensed healthcare professional for medical decisions.